File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/cancers15194850
- Scopus: eid_2-s2.0-85173805246
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Nasopharynx Battlefield: Cellular Immune Responses Mediated by Midkine in Nasopharyngeal Carcinoma and COVID-19
Title | Nasopharynx Battlefield: Cellular Immune Responses Mediated by Midkine in Nasopharyngeal Carcinoma and COVID-19 |
---|---|
Authors | |
Keywords | cellular immunity COVID-19 ligand–receptor pairs midkine nasopharyngeal carcinoma |
Issue Date | 4-Oct-2023 |
Publisher | MDPI |
Citation | Cancers, 2023, v. 15, n. 19 How to Cite? |
Abstract | Clinical evidence suggests that the severe respiratory illness coronavirus disease 2019 (COVID-19) is often associated with a cytokine storm that results in dysregulated immune responses. Prolonged COVID-19 positivity is thought to disproportionately affect cancer patients. With COVID-19 disrupting the delivery of cancer care, it is crucial to gain momentum and awareness of the mechanistic intersection between these two diseases. This review discusses the role of the cytokine midkine (MK) as an immunomodulator in patients with COVID-19 and nasopharyngeal carcinoma (NPC), both of which affect the nasal cavity. We conducted a review and analysis of immunocellular similarities and differences based on clinical studies, research articles, and published transcriptomic datasets. We specifically focused on ligand–receptor pairs that could be used to infer intercellular communication, as well as the current medications used for each disease, including NPC patients who have contracted COVID-19. Based on our findings, we recommend close monitoring of the MK axis to maintain the desirable effects of therapeutic regimens in fighting both NPC and COVID-19 infections. |
Persistent Identifier | http://hdl.handle.net/10722/343549 |
ISSN | 2021 Impact Factor: 6.575 2020 SCImago Journal Rankings: 1.818 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kam, Ngar-Woon | - |
dc.contributor.author | Lau, Cho-Yiu | - |
dc.contributor.author | Che, Chi-Ming | - |
dc.contributor.author | Lee, Victor Ho-Fun | - |
dc.date.accessioned | 2024-05-14T05:21:23Z | - |
dc.date.available | 2024-05-14T05:21:23Z | - |
dc.date.issued | 2023-10-04 | - |
dc.identifier.citation | Cancers, 2023, v. 15, n. 19 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | http://hdl.handle.net/10722/343549 | - |
dc.description.abstract | <p>Clinical evidence suggests that the severe respiratory illness coronavirus disease 2019 (COVID-19) is often associated with a cytokine storm that results in dysregulated immune responses. Prolonged COVID-19 positivity is thought to disproportionately affect cancer patients. With COVID-19 disrupting the delivery of cancer care, it is crucial to gain momentum and awareness of the mechanistic intersection between these two diseases. This review discusses the role of the cytokine midkine (MK) as an immunomodulator in patients with COVID-19 and nasopharyngeal carcinoma (NPC), both of which affect the nasal cavity. We conducted a review and analysis of immunocellular similarities and differences based on clinical studies, research articles, and published transcriptomic datasets. We specifically focused on ligand–receptor pairs that could be used to infer intercellular communication, as well as the current medications used for each disease, including NPC patients who have contracted COVID-19. Based on our findings, we recommend close monitoring of the MK axis to maintain the desirable effects of therapeutic regimens in fighting both NPC and COVID-19 infections.</p> | - |
dc.language | eng | - |
dc.publisher | MDPI | - |
dc.relation.ispartof | Cancers | - |
dc.subject | cellular immunity | - |
dc.subject | COVID-19 | - |
dc.subject | ligand–receptor pairs | - |
dc.subject | midkine | - |
dc.subject | nasopharyngeal carcinoma | - |
dc.title | Nasopharynx Battlefield: Cellular Immune Responses Mediated by Midkine in Nasopharyngeal Carcinoma and COVID-19 | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/cancers15194850 | - |
dc.identifier.scopus | eid_2-s2.0-85173805246 | - |
dc.identifier.volume | 15 | - |
dc.identifier.issue | 19 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.issnl | 2072-6694 | - |